Genetic counseling and testing for females at elevated risk for breast cancer: Protocol for the randomized controlled trial of the Know Your Risk intervention
Contemporary Clinical Trials · 2023
DOI: 10.1016/j.cct.2023.107323 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2023. Verfasst von Kevin Sweet und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Human Genetics, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer …. Hauptthemen laut MEDLINE: Genetic Counseling, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND: Genetic counseling and testing have an important role in the care of patients at elevated risk for breast cancer. However, conventional pre- and post-test genetic counseling is labor and time intensive, less accessible for patients living outside major urban centers, and impractical on a large scale. A patient-driven approach to genetic counseling and testing may increase access, improve patients' experiences, affect efficiency of clinical practice, and help meet workforce demand. The objective of this 2-arm randomized controlled trial is to determine the efficacy of Know Your Risk (KYR), a genetic counseling patient preference intervention. METHODS: Females (n = 1000) at elevated risk (>20% lifetime) for breast cancer will be randomized to the KYR intervention or conventional genetic counseling. The study will provide comprehensive assessment of breast cancer risk by multigene panel testing and validated polygenic risk score. Primary outcome is adherence to National Comprehensive Cancer Network guidelines for a clinical encounter every 6-12 months and an annual mammogram (breast MRI if recommended) determined by medical record review. Secondary outcomes include adherence to other recommended cancer screening tests determined by medical record review and changes in breast cancer knowledge, perception of risk, post-test/counseling distress, and satisfaction with counseling by completion of three surveys during the study. Study aims will be evaluated for non-inferiority of the KYR intervention compared to conventional genetic counseling. CONCLUSION: If efficacious, the KYR intervention has the potential to improve patients' experience and may change how genetic counseling is delivered, inform best practices, and reduce workforce burden. TRIAL REGISTRATION: ClinicalTrials.govNCT05325151.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Human Genetics, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Electronic addre…
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Division of Health Behavior and Health Promotion, College of Public Health, The Ohio State University, Columbus, OH, USA.
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH, USA.
- Division of Human Genetics, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
- Division of Human Genetics, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Division of Bioe…
- Division of Human Genetics, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Department of Ca…
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- National Cancer Institute
- National Center for Advancing Translational Sciences
- The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute
- National Institutes of Health
Zitieren
APA
Sweet, K., Reiter, P. L., Schnell, P. M., Senter, L., Shane-Carson, K. P., Aeilts, A., Cooper, J., Spears, C., Brown, J., Toland, A. E., Agnese, D. M., & Katz, M. L. (2023). Genetic counseling and testing for females at elevated risk for breast cancer: Protocol for the randomized controlled trial of the Know Your Risk intervention. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2023.107323
Vancouver
Sweet K, Reiter PL, Schnell PM, Senter L, Shane-Carson KP, Aeilts A, et al. Genetic counseling and testing for females at elevated risk for breast cancer: Protocol for the randomized controlled trial of the Know Your Risk intervention. Contemporary Clinical Trials. 2023. doi:10.1016/j.cct.2023.107323
BibTeX
@article{Sweet2023,
author = {Sweet, Kevin and Reiter, Paul L and Schnell, Patrick M and Senter, Leigha and Shane-Carson, Kate P and Aeilts, Amber and Cooper, Julia and Spears, Christina and Brown, Jordan and Toland, Amanda E and Agnese, Doreen M and Katz, Mira L},
title = {Genetic counseling and testing for females at elevated risk for breast cancer: Protocol for the randomized controlled trial of the Know Your Risk intervention},
journal = {Contemporary Clinical Trials},
year = {2023},
doi = {10.1016/j.cct.2023.107323}
}
EUVIMED